Briefing: Novo’s subscription model raises questions about pharma-telehealth tie-ups

Novo's introduction of a subscription model for its products has sparked discussions about the potential impacts on partnerships between pharmaceutical companies and telehealth platforms.

This model could influence how medications are accessed and managed through telehealth services, particularly as the industry navigates evolving regulatory environments.

The delayed FDA decision for Orca Bio further complicates the landscape, highlighting the need for clear frameworks that govern the intersection of pharmaceuticals and telehealth.